Domestic supply of the domestic biosimilar of ‘Humira’ has begun in full scale.

According to industry sources, Adalloce, a biosimilar of the TNF- alpha blocker Humira(adalimumab)’s that was developed by Samsung Bioepis and sold by Yuhan Corporation in Korea, passed the Drug Committees (DCs) of 20 medical institutions including the Big-5s such as the Samsung Medical Center (SMC), Asan Medical Center (AMC), and Severance Hospital.

Adalloce was the first biosimilar adalimumab product to receive marketing approval in Korea. It is a tumor necrosis factor (TNF)-alpha-blocker that is used to treat autoimmune conditions including rheumatoid arthritis, ankylosing spondylitis, and Crohn's dise